Takano Tomonori, Aiba Hiroyuki, Kaku Mitsuo, Kunishima Hiroyuki
Department of Infectious Diseases, St. Marianna University School of Medicine, Kawasaki, Japan.
J Anus Rectum Colon. 2025 Jan 25;9(1):25-32. doi: 10.23922/jarc.2024-078. eCollection 2025.
Fever and diarrhea are the common symptoms of infection (CDI); however, pseudomembranous enteritis, megacolonization, and paralytic ileus have been observed in severe cases. spores are resistant to several types of disinfectants. Thus, they are often the causative pathogens of healthcare-associated infections. Rapid diagnostic tests based on glutamate dehydrogenase and toxins are the mainstay of CDI laboratory diagnosis owing to their simplicity. CDI can be diagnosed with high specificity using the nucleic acid amplification test, a genetic test for toxins. The risk factors for CDI include age ≥65 years; history of antimicrobial use; previous hospitalization; history of gastrointestinal surgery, chronic kidney disease, or inflammatory bowel disease; nasal tube feeding; and use of proton pump inhibitors and histamine H2 receptor antagonists. The risk of CDI development persists even 1 year after discontinuation of proton pump inhibitor use. Furthermore, colorectal surgery and radical cystectomy with urinary diversion are associated with high incidences of postoperative CDI. The choice of therapeutic agent depends on the severity of the disease and recurrence. However, a combination of oral or nasogastric vancomycin, intracolonic vancomycin, and intravenous metronidazole can be considered in patients with toxic megacolonization and paralytic ileus. In January 2024, the European Committee on Antimicrobial Susceptibility Testing established a breakpoint for fidaxomicin (minimum inhibitory concentration breakpoint > 2 mg/L) against . Rapid progress has been achieved in CDI treatment. Thus, multidisciplinary teams must collaborate to diagnose, treat, and control CDI.
发热和腹泻是艰难梭菌感染(CDI)的常见症状;然而,在严重病例中已观察到假膜性肠炎、巨结肠形成和麻痹性肠梗阻。芽孢对多种消毒剂具有抗性。因此,它们常常是医疗保健相关感染的致病病原体。基于谷氨酸脱氢酶和毒素的快速诊断测试因其简便性而成为CDI实验室诊断的主要手段。使用核酸扩增试验(一种检测毒素的基因检测方法)可以高特异性地诊断CDI。CDI的风险因素包括年龄≥65岁;抗菌药物使用史;既往住院史;胃肠道手术史、慢性肾脏病或炎症性肠病病史;鼻饲;以及使用质子泵抑制剂和组胺H2受体拮抗剂。即使停用质子泵抑制剂1年后,发生CDI的风险仍然存在。此外,结直肠手术和带尿路改道的根治性膀胱切除术与术后CDI的高发生率相关。治疗药物的选择取决于疾病的严重程度和复发情况。然而,对于有毒性巨结肠形成和麻痹性肠梗阻的患者,可以考虑联合使用口服或鼻饲万古霉素、结肠内万古霉素和静脉注射甲硝唑。2024年1月,欧洲抗菌药物敏感性测试委员会确定了非达霉素对艰难梭菌的折点(最低抑菌浓度折点>2mg/L)。CDI治疗已取得快速进展。因此,多学科团队必须协作以诊断、治疗和控制CDI。